Health technology assessments and pharmaceutical pricing - .PDF file.
By Dr Wolfgang A Rehmann and Diana Heimhalt
Pharmaceutical benefit assessments play an increasingly important role in refunds by the national health services. In most European countries, a drug has to successfully pass a post-approval benefit evaluation before it becomes available in the publicly funded healthcare system. Most European member states have implemented health technology assessments-based pharmaceutical evaluation schemes; their results form the basis for pharmaceutical pricing.
The EU member states maintain different pricing systems. There are basically two variations…
If you are registered and logged in to the site, click on the link below to read the rest of the Taylor Wessing briefing. If not, please register or sign in with your details below.